We are a company focused on the development of new treatment options for women and couples struggling with infertility. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC℠) cells – immature egg cells found within the outer ovarian cortex.
OvaPrime is a potential fertility treatment that could help restore a woman’s egg production and OvaTure is a potential fertility treatment that eliminates the need for ovarian hormone stimulation. OvaScience’s AUGMENT treatment, designed to improve embryo development and pregnancy rates, is available in Japan under an exclusive license to IVF Japan. OvaScience’s treatments are not available in the United States.
H.C. Wainwright & Co., LLC
OvaScience, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding OvaScience, Inc.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of OvaScience, Inc. or its management. OvaScience, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.